Prevascularized constructs for implantation to provide blood perfusion

Patent metadata

Field	Value
Publication number	US-9506040-B2
Application number	US-46404109-A
Country	US
Kind code	B2
Filing date	May 11, 2009
Priority date	Mar 30, 2001
Publication date	Nov 29, 2016
Grant date	Nov 29, 2016

Abstract

This application discloses methods and materials for preparing functional microvascular beds in the laboratory. These prevascularized constructs can be used to vascularize engineered tissue constructs or to revascularize damaged or diseased tissues or organs following implantation. The prevascularized constructs may also deliver genetically engineered gene products to the bloodstream.

First claim

What is claimed is:

1. A method for expanding substantially intact microvessel fragments construct adapted for use in vascularizing a tissue or an organ in a subject, said method comprising:
a. isolating microvessel fragments;
b. combining said isolated microvessel fragments with a liquid solution of biocompatible culture matrix to produce a solution of prevascularized construct comprising said isolated microvessel fragments; and
c. culturing and expanding said microvessel fragments in said step (b) under conditions sufficient to produce a three dimensional culture matrix of prevascularized construct comprising an expanded microvessel fragments that is adapted for use in vascularizing a tissue or an organ of said subject.

2. The method of claim 1 , wherein said three dimensional culture matrix comprises at least one component selected from the group consisting of collagen, a fibrin, a gelatin, an alginate, a hydrogel, a dextran, a chemically-crosslinkable dextran, a photo-crosslinkable dextran, ePTFE, PTFE, PGA, PLA, PLGA, PET, a nylon, a vinyl, a silk, and a combination thereof.

3. The method of claim 1 further comprising the steps of adding one or more components selected from the group consisting of at least one chemokine, at least one antibiotic, at least one drug, at least one analgesic agent, at least one anti-inflammatory agent, at least one immunosuppressive agent, and combinations thereof in or after any of steps (b) or (c).

4. The method of claim 1 , wherein said microvessel fragments are cultured for 7-11 days.

5. The method of claim 1 further comprising the step of adding a cytokine in or after any of steps (b) or (c).

6. The method of claim 5 , wherein said cytokine comprises VEGF, PDGF, or a combination thereof.

7. The method of claim 1 further comprising the step of adding one or more stem cells, stromal cells, Relevant Cells, or combinations thereof in or after any of steps (b) or (c).

8. The method of claim 1 , wherein said microvessel fragments are isolated from a tissue selected from the group consisting of skin, muscle, lung, mesentery and adipose tissue.

Assignees

• Williams Stuart K
• Hoying James B
• Shepherd Benjamin R
• Univ Arizona

Inventors

• Williams Stuart K
• Hoying James B
• Shepherd Benjamin R

Classifications

• A61K48/00

  Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy · CPC title

• C12N2533/54

  Collagen; Gelatin · CPC title

• C12N2501/20

  Cytokines; Chemokines · CPC title

• C12N5/0691

  Vascular smooth muscle cells; 3D culture thereof, e.g. models of blood vessels · CPC title

• C12N2533/56

  Fibrin; Thrombin · CPC title